Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Boris Draznin to Humans

This is a "connection" page, showing publications Boris Draznin has written about Humans.

 
Connection Strength
  
 
 
0.483
  
  1. Draznin B, Sadhu A, Schutta M, Ramirez BF, Polsky S, Shubrook JH, Low Wang CC. Authors' Reply: Improved Access to Quality Diabetes Care in the United States: Where Do We Go From Here? Endocr Pract. 2021 07; 27(7):760-761.
    View in: PubMed
    Score: 0.021
  2. Draznin B, Sadhu A, Schutta M, Ramirez BF, Polsky S, Shubrook JH, Low Wang CC. The Diabetes Epidemic and Diabetes Fellowships for Primary Care Physicians. Endocr Pract. 2021 Jun; 27(6):636-637.
    View in: PubMed
    Score: 0.021
  3. Draznin B, Hirsch IB. Time to Follow the Evidence: Glycemic Control and Cardiovascular Benefits of New Diabetes Medications. Am J Med. 2021 04; 134(4):420-422.
    View in: PubMed
    Score: 0.020
  4. Hirsch IB, Draznin B. Transition of Patients to and from Insulin Degludec: A Clinical Challenge. J Clin Endocrinol Metab. 2020 06 01; 105(6).
    View in: PubMed
    Score: 0.020
  5. Draznin B, Nathan DM, Korytkowski MT, McDonnell ME, Golden SH, Schutta MH, Cefalu WT. Guidelines Versus Guidelines: What's Best for the Patient? Ann Intern Med. 2018 08 07; 169(3):186-187.
    View in: PubMed
    Score: 0.017
  6. Draznin B, Kahn PA, Wagner N, Hirsch IB, Korytkowski M, Harlan DM, McDonnell ME, Gabbay RA. Clinical Diabetes Centers of Excellence: A Model for Future Adult Diabetes Care. J Clin Endocrinol Metab. 2018 03 01; 103(3):809-812.
    View in: PubMed
    Score: 0.017
  7. Wang YJ, Seggelke S, Hawkins RM, Gibbs J, Lindsay M, Hazlett I, Low Wang CC, Rasouli N, Young KA, Draznin B. IMPACT OF GLUCOSE MANAGEMENT TEAM ON OUTCOMES OF HOSPITALIZARON IN PATIENTS WITH TYPE 2 DIABETES ADMITTED TO THE MEDICAL SERVICE. Endocr Pract. 2016 12; 22(12):1401-1405.
    View in: PubMed
    Score: 0.015
  8. Low Wang CC, Draznin B. USE OF NPH INSULIN FOR GLUCOCORTICOID-INDUCED HYPERGLYCEMIA. Endocr Pract. 2016 Feb; 22(2):271-3.
    View in: PubMed
    Score: 0.014
  9. Hellman R, Draznin B. Do we need to broaden the scope of inpatient diabetes education to include our faculty? Endocr Pract. 2015 Apr; 21(4):448-9.
    View in: PubMed
    Score: 0.014
  10. Draznin B, Wang Y, Seggelke S, Hawkins RM, Gibbs J, Bridenstine M, Rasouli N, Wang CL. Glycemic control and outcomes of hospitalization in noncritically ill patients with type 2 diabetes admitted with cardiac problems or infections. Endocr Pract. 2014 Dec; 20(12):1303-8.
    View in: PubMed
    Score: 0.013
  11. Seggelke SA, Hawkins RM, Gibbs J, Rasouli N, Wang CC, Draznin B. Effect of glargine insulin delivery method (pen device versus vial/syringe) on glycemic control and patient preferences in patients with type 1 and type 2 diabetes. Endocr Pract. 2014 Jun; 20(6):536-9.
    View in: PubMed
    Score: 0.013
  12. Seggelke SA, Hawkins RM, Gibbs J, Rasouli N, Wang C, Draznin B. Transitional care clinic for uninsured and medicaid-covered patients with diabetes mellitus discharged from the hospital: a pilot quality improvement study. Hosp Pract (1995). 2014 Feb; 42(1):46-51.
    View in: PubMed
    Score: 0.013
  13. Draznin B, Gilden J, Golden SH, Inzucchi S. Response to comment on: Draznin et al. Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action. Diabetes Care 2013;36:1807-1814. Diabetes Care. 2013 Dec; 36(12):e220.
    View in: PubMed
    Score: 0.012
  14. Draznin B, Gilden J, Golden SH, Inzucchi SE, Baldwin D, Bode BW, Boord JB, Braithwaite SS, Cagliero E, Dungan KM, Falciglia M, Figaro MK, Hirsch IB, Klonoff D, Korytkowski MT, Kosiborod M, Lien LF, Magee MF, Masharani U, Maynard G, McDonnell ME, Moghissi ES, Rasouli N, Rubin DJ, Rushakoff RJ, Sadhu AR, Schwartz S, Seley JJ, Umpierrez GE, Vigersky RA, Low CC, Wexler DJ. Pathways to quality inpatient management of hyperglycemia and diabetes: a call to action. Diabetes Care. 2013 Jul; 36(7):1807-14.
    View in: PubMed
    Score: 0.012
  15. Low Wang CC, Draznin B. Practical approach to management of inpatient hyperglycemia in select patient populations. Hosp Pract (1995). 2013 Apr; 41(2):45-53.
    View in: PubMed
    Score: 0.012
  16. Rasouli N, Seggelke S, Gibbs J, Hawkins RM, Casciano ML, Cohlmia E, Taylor-Cousar J, Wang C, Pereira R, Hsia E, Draznin B. Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions. J Diabetes Sci Technol. 2012 Sep 01; 6(5):1038-44.
    View in: PubMed
    Score: 0.011
  17. Hsia E, Seggelke S, Gibbs J, Hawkins RM, Cohlmia E, Rasouli N, Wang C, Kam I, Draznin B. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab. 2012 Sep; 97(9):3132-7.
    View in: PubMed
    Score: 0.011
  18. Draznin B, Wang C, Adochio R, Leitner JW, Cornier MA. Effect of dietary macronutrient composition on AMPK and SIRT1 expression and activity in human skeletal muscle. Horm Metab Res. 2012 Sep; 44(9):650-5.
    View in: PubMed
    Score: 0.011
  19. Hsia E, Seggelke SA, Gibbs J, Rasouli N, Draznin B. Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy. Nutr Clin Pract. 2011 Dec; 26(6):714-7.
    View in: PubMed
    Score: 0.011
  20. Hsia E, Draznin B. Intensive control of diabetes in the hospital: why, how, and what is in the future? J Diabetes Sci Technol. 2011 Nov 01; 5(6):1596-601.
    View in: PubMed
    Score: 0.011
  21. Seggelke SA, Gibbs J, Draznin B. Pilot study of using neutral protamine Hagedorn insulin to counteract the effect of methylprednisolone in hospitalized patients with diabetes. J Hosp Med. 2011 Mar; 6(3):175-6.
    View in: PubMed
    Score: 0.010
  22. Draznin B. Mitogenic action of insulin: friend, foe or 'frenemy'? Diabetologia. 2010 Feb; 53(2):229-33.
    View in: PubMed
    Score: 0.009
  23. Pereira RI, Leitner JW, Erickson C, Draznin B. Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3'-kinase. Life Sci. 2008 Nov 07; 83(19-20):638-43.
    View in: PubMed
    Score: 0.009
  24. Muntoni S, Muntoni S, Draznin B. Effects of chronic hyperinsulinemia in insulin-resistant patients. Curr Diab Rep. 2008 Jun; 8(3):233-8.
    View in: PubMed
    Score: 0.009
  25. Reusch JE, Draznin BB. Atherosclerosis in diabetes and insulin resistance. Diabetes Obes Metab. 2007 Jul; 9(4):455-63.
    View in: PubMed
    Score: 0.008
  26. Thureen P, Reece M, Rodden D, Barbour L, Chappell J, Leitner JW, Jones RO, Draznin B. Increased farnesylation of p21-Ras and neonatal macrosomia in women with gestational diabetes. J Pediatr. 2006 Dec; 149(6):871-3.
    View in: PubMed
    Score: 0.008
  27. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes. 2006 Aug; 55(8):2392-7.
    View in: PubMed
    Score: 0.007
  28. Cornier MA, Bessesen DH, Gurevich I, Leitner JW, Draznin B. Nutritional upregulation of p85alpha expression is an early molecular manifestation of insulin resistance. Diabetologia. 2006 Apr; 49(4):748-54.
    View in: PubMed
    Score: 0.007
  29. Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, Vo Y, McCurdy CE, Yakar S, Leroith D, Kahn CR, Cantley LC, Friedman JE, Draznin B. Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem. 2005 Nov 11; 280(45):37489-94.
    View in: PubMed
    Score: 0.007
  30. Cornier MA, Donahoo WT, Pereira R, Gurevich I, Westergren R, Enerback S, Eckel PJ, Goalstone ML, Hill JO, Eckel RH, Draznin B. Insulin sensitivity determines the effectiveness of dietary macronutrient composition on weight loss in obese women. Obes Res. 2005 Apr; 13(4):703-9.
    View in: PubMed
    Score: 0.007
  31. Wang CC, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes. 2004 Nov; 53(11):2735-40.
    View in: PubMed
    Score: 0.007
  32. Finlayson CA, Chappell J, Leitner JW, Goalstone ML, Garrity M, Nawaz S, Ciaraldi TP, Draznin B. Enhanced insulin signaling via Shc in human breast cancer. Metabolism. 2003 Dec; 52(12):1606-11.
    View in: PubMed
    Score: 0.006
  33. Barbour LA, Shao J, Qiao L, Leitner W, Anderson M, Friedman JE, Draznin B. Human placental growth hormone increases expression of the p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Endocrinology. 2004 Mar; 145(3):1144-50.
    View in: PubMed
    Score: 0.006
  34. Montagnani M, Golovchenko I, Kim I, Koh GY, Goalstone ML, Mundhekar AN, Johansen M, Kucik DF, Quon MJ, Draznin B. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem. 2002 Jan 18; 277(3):1794-9.
    View in: PubMed
    Score: 0.005
  35. Goalstone ML, Leitner JW, Berhanu P, Sharma PM, Olefsky JM, Draznin B. Insulin signals to prenyltransferases via the Shc branch of intracellular signaling. J Biol Chem. 2001 Apr 20; 276(16):12805-12.
    View in: PubMed
    Score: 0.005
  36. Chappell J, Golovchenko I, Wall K, Stjernholm R, Leitner JW, Goalstone M, Draznin B. Potentiation of Rho-A-mediated lysophosphatidic acid activity by hyperinsulinemia. J Biol Chem. 2000 Oct 13; 275(41):31792-7.
    View in: PubMed
    Score: 0.005
  37. Draznin B, Miles P, Kruszynska Y, Olefsky J, Friedman J, Golovchenko I, Stjernholm R, Wall K, Reitman M, Accili D, Cooksey R, McClain D, Goalstone M. Effects of insulin on prenylation as a mechanism of potentially detrimental influence of hyperinsulinemia. Endocrinology. 2000 Apr; 141(4):1310-6.
    View in: PubMed
    Score: 0.005
  38. LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, Hirsch IB, McDonnell ME, Molitch ME, Murad MH, Sinclair AJ. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019 05 01; 104(5):1520-1574.
    View in: PubMed
    Score: 0.005
  39. Sowers JR, Draznin B. Insulin, cation metabolism and insulin resistance. J Basic Clin Physiol Pharmacol. 1998; 9(2-4):223-33.
    View in: PubMed
    Score: 0.004
  40. Goalstone ML, Draznin B. Insulin signaling. West J Med. 1997 Sep; 167(3):166-73.
    View in: PubMed
    Score: 0.004
  41. Grodzinsky A, Arnold SV, Jacob D, Draznin B, Kosiborod M. THE IMPACT OF CARDIOVASCULAR DRUGS ON GLYCEMIC CONTROL: A REVIEW. Endocr Pract. 2017 Mar; 23(3):363-371.
    View in: PubMed
    Score: 0.004
  42. Carel K, DePaolo D, Reusch JE, Leitner JW, Draznin B. Reduced phosphorylation of mitogen-activated protein kinase kinase in response to insulin in cells with truncated C-terminal domain of insulin receptor. Endocrinology. 1996 Jun; 137(6):2362-6.
    View in: PubMed
    Score: 0.004
  43. DePaolo D, Reusch JE, Carel K, Bhuripanyo P, Leitner JW, Draznin B. Functional interactions of phosphatidylinositol 3-kinase with GTPase-activating protein in 3T3-L1 adipocytes. Mol Cell Biol. 1996 Apr; 16(4):1450-7.
    View in: PubMed
    Score: 0.004
  44. Klonoff DC, Draznin B, Drincic A, Dungan K, Gianchandani R, Inzucchi SE, Nichols JH, Rice MJ, Seley JJ. PRIDE Statement on the Need for a Moratorium on the CMS Plan to Cite Hospitals for Performing Point-of-Care Capillary Blood Glucose Monitoring on Critically Ill Patients. J Clin Endocrinol Metab. 2015 Oct; 100(10):3607-12.
    View in: PubMed
    Score: 0.004
  45. Reusch JE, Hsieh P, Bhuripanyo P, Carel K, Leitner JW, Olefsky JM, Draznin B. Insulin inhibits nuclear phosphatase activity: requirement for the C-terminal domain of the insulin receptor. Endocrinology. 1995 Jun; 136(6):2464-9.
    View in: PubMed
    Score: 0.003
  46. Reusch JE, Bhuripanyo P, Carel K, Leitner JW, Hsieh P, DePaolo D, Draznin B. Differential requirement for p21ras activation in the metabolic signaling by insulin. J Biol Chem. 1995 Feb 03; 270(5):2036-40.
    View in: PubMed
    Score: 0.003
  47. Draznin B. Cytosolic calcium and insulin resistance. Am J Kidney Dis. 1993 Jun; 21(6 Suppl 3):32-8.
    View in: PubMed
    Score: 0.003
  48. Begum N, Olefsky JM, Draznin B. Mechanism of impaired metabolic signaling by a truncated human insulin receptor. Decreased activation of protein phosphatase 1 by insulin. J Biol Chem. 1993 Apr 15; 268(11):7917-22.
    View in: PubMed
    Score: 0.003
  49. Wang CC, Adochio RL, Leitner JW, Abeyta IM, Draznin B, Cornier MA. Acute effects of different diet compositions on skeletal muscle insulin signalling in obese individuals during caloric restriction. Metabolism. 2013 Apr; 62(4):595-603.
    View in: PubMed
    Score: 0.003
  50. Byyny RL, LoVerde M, Lloyd S, Mitchell W, Draznin B. Cytosolic calcium and insulin resistance in elderly patients with essential hypertension. Am J Hypertens. 1992 Jul; 5(7):459-64.
    View in: PubMed
    Score: 0.003
  51. Bergouignan A, Gozansky WS, Barry DW, Leitner W, MacLean PS, Hill JO, Draznin B, Melanson EL. Increasing dietary fat elicits similar changes in fat oxidation and markers of muscle oxidative capacity in lean and obese humans. PLoS One. 2012; 7(1):e30164.
    View in: PubMed
    Score: 0.003
  52. Draznin B. Cytosolic calcium: a new factor in insulin resistance? Diabetes Res Clin Pract. 1991 Mar; 11(3):141-5.
    View in: PubMed
    Score: 0.003
  53. Murakami K, Wilk J, Nishida K, Sussman KE, Draznin B. Hep-G2 glucose transporter gene polymorphism in Caucasian, black, Hispanic and Japanese patients with NIDDM. Diabetes Res Clin Pract. 1990 May-Jun; 9(2):115-21.
    View in: PubMed
    Score: 0.002
  54. Segal S, Lloyd S, Sherman N, Sussman K, Draznin B. Postprandial changes in cytosolic free calcium and glucose uptake in adipocytes in obesity and non-insulin-dependent diabetes mellitus. Horm Res. 1990; 34(1):39-44.
    View in: PubMed
    Score: 0.002
  55. Nadeau KJ, Regensteiner JG, Bauer TA, Brown MS, Dorosz JL, Hull A, Zeitler P, Draznin B, Reusch JE. Insulin resistance in adolescents with type 1 diabetes and its relationship to cardiovascular function. J Clin Endocrinol Metab. 2010 Feb; 95(2):513-21.
    View in: PubMed
    Score: 0.002
  56. Nadeau KJ, Zeitler PS, Bauer TA, Brown MS, Dorosz JL, Draznin B, Reusch JE, Regensteiner JG. Insulin resistance in adolescents with type 2 diabetes is associated with impaired exercise capacity. J Clin Endocrinol Metab. 2009 Oct; 94(10):3687-95.
    View in: PubMed
    Score: 0.002
  57. Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA. Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest. 1988 Dec; 82(6):1848-52.
    View in: PubMed
    Score: 0.002
  58. Draznin B. Intracellular calcium, insulin secretion, and action. Am J Med. 1988 Nov 28; 85(5A):44-58.
    View in: PubMed
    Score: 0.002
  59. Glugla M, Draznin B. Treatment of impotence with vacuum-operated erection assistance device. Diabetes Care. 1988 May; 11(5):445-6.
    View in: PubMed
    Score: 0.002
  60. Barbour LA, Shao J, Qiao L, Pulawa LK, Jensen DR, Bartke A, Garrity M, Draznin B, Friedman JE. Human placental growth hormone causes severe insulin resistance in transgenic mice. Am J Obstet Gynecol. 2002 Mar; 186(3):512-7.
    View in: PubMed
    Score: 0.001
  61. Draznin B, Burstein PJ, Heinrich UE, Johnson CB, Emler CA, Schalch DS. Insulin-like growth factor and its carrier protein in hypopituitary and hypothyroid children and adults. Clin Endocrinol (Oxf). 1980 Feb; 12(2):137-42.
    View in: PubMed
    Score: 0.001
  62. Draznin B, Ayalon D, Hoerer E, Oberman Z, Harell A, Ravid R, Laurian L. Effect of diphenylhydantoin on patterns of insulin secretion in obese subjects. Acta Diabetol Lat. 1977 Jan-Apr; 14(1-2):51-61.
    View in: PubMed
    Score: 0.001
  63. Sasaoka T, Langlois WJ, Bai F, Rose DW, Leitner JW, Decker SJ, Saltiel A, Gill GN, Kobayashi M, Draznin B, Olefsky JM. Involvement of ErbB2 in the signaling pathway leading to cell cycle progression from a truncated epidermal growth factor receptor lacking the C-terminal autophosphorylation sites. J Biol Chem. 1996 Apr 05; 271(14):8338-44.
    View in: PubMed
    Score: 0.001
  64. Sasaoka T, Rose DW, Jhun BH, Saltiel AR, Draznin B, Olefsky JM. Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem. 1994 May 06; 269(18):13689-94.
    View in: PubMed
    Score: 0.001
  65. Jhun BH, Meinkoth JL, Leitner JW, Draznin B, Olefsky JM. Insulin and insulin-like growth factor-I signal transduction requires p21ras. J Biol Chem. 1994 Feb 25; 269(8):5699-704.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)